Cefa Safe 300 mg Intramammary Suspension for dairy cows at drying-off

Authorised

- Cefapirin benzathine

Product identification

Medicine name:
Cefa Safe 300 mg Intramammary Suspension for dairy cows at drying-off
Cefa-Safe 300 mg, intramaminė suspensija pieninėms karvėms užtrūkinimo metu

Active substance:
Cefapirin benzathine

Target species:
Cattle (dairy cow at drying-off)

Route of administration:
Intramammary use

Product details

Active substance and strength:
Cefapirin benzathine
383.30 milligram(s) / 1.00 Applicator

Pharmaceutical form:
Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

- **Cattle (dairy cow at drying-off)**
  - Meat and offal. 14 day
  - Milk. 24 hour

24 hours after calving if the interval between treatment and calving is 32 days or longer.

  - Milk. 33 day

33 days after treatment if the interval between treatment and calving is less than 32 days

---

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ51DB08

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Lithuania

Package description:
(ID2) 1440 millilitre(s): Behältnis (Plastic) with 144 Syringe (Low Density PolyEthylene) each with 10 millilitre(s), closed with Lid (Low Density PolyEthylene)
(ID1) 200 millilitre(s): Box (Cardboard) with 20 Syringe (Low Density PolyEthylene) each with 10 millilitre(s), closed with Lid (Low Density PolyEthylene)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
7/11/2021

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
State Food And Veterinary Service

Authorisation number:
LT/2/21/2688/001-002

Date of authorisation status change:
7/11/2021

Reference member state:
Germany

Procedure number:
DE/V/0339/001

Concerned member states:
Austria Belgium Croatia Cyprus Czechia Estonia Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Portugal Romania Slovakia

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

RV2688.pdf
